The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases

På svenska

Author

  • Paolo G. V. Martini
  • Lynette C. Cook
  • Scott Alderucci
  • Angela W. Norton
  • Dianna M. Lundberg
  • Susan M. Fish
  • Knut Langsetmo
  • Göran Jönsson
  • Christian Lood
  • Birgitta Gullstrand
  • Kate J. Zaleski
  • Nancy Savioli
  • Jason Lottherand
  • Charles Bedard
  • John Gill
  • Michael F. Concino
  • Michael W. Heartlein
  • Lennart Truedsson
  • Jan L. Powell
  • Arthur O. Tzianabos
Show all

Summary, in English

Background: Complement C2 deficiency is the most common genetically determined complete complement deficiency and is associated with a number of diseases. Most prominent are the associations with recurrent serious infections in young children and the development of systemic lupus erythematosus (SLE) in adults. The links with these diseases reflect the important role complement C2 plays in both innate immunity and immune tolerance. Infusions with normal fresh frozen plasma for the treatment of associated disease have demonstrated therapeutic effects but so far protein replacement therapy has not been evaluated. Results: Human complement C2 was cloned and expressed in a mammalian cell line. The purity of recombinant human C2 (rhC2) was greater than 95% and it was characterized for stability and activity. It was sensitive to C1s cleavage and restored classical complement pathway activity in C2-deficient serum both in a complement activation ELISA and a hemolytic assay. Furthermore, rhC2 could increase C3 fragment deposition on the human pathogen Streptococcus pneumoniae in C2-deficient serum to levels equal to those with normal serum. Conclusions: Taken together these data suggest that recombinant human C2 can restore classical complement pathway activity and may serve as a potential therapeutic for recurring bacterial infections or SLE in C2-deficient patients.

Publishing year

2010

Language

English

Publication/Series

BMC Immunology

Volume

11

Document type

Journal article

Publisher

BioMed Central (BMC)

Topic

  • Immunology in the medical area

Status

Published

ISBN/ISSN/Other

  • ISSN: 1471-2172